采用新型高敏心肌肌钙蛋白I检测的疑似心肌梗死评估路径的潜在影响
该回顾性分析纳入2019年6月至9月急诊疑似心肌梗死患者935例,所有患者均接受常规cTnI检测(AccuTnI+3)并按常规路径诊治,同时留取hs-cTnI(Access hsTnI)标本但医生对结果设盲;研究者用hs-cTnI值回顾性判定诊断、处置及30天主要不良心脏事件可能性。结果显示常规路径与新型hs-cTnI路径的出院后30天非预期主要不良心脏事件率均为0/935(0%,95%CI 0%至0.4%)。hs-cTnI较常规检测的异常升高率更高(29% vs 19%),心肌梗死诊断率(9% vs 8%)与住院率(42% vs 43%)相近。作者结论认为该新型路径具有可接受的低30天主要不良心脏事件率。
要点
- 935例疑似心肌梗死急诊患者中,常规路径与Access hsTnI路径的出院后30天非预期MACE率均为0/935(0%,95%CI 0%至0.4%)。
- hs-cTnI检测的异常升高率为29%(95%CI 26%至32%),高于常规cTnI的19%(95%CI 17%至22%)。
- hs-cTnI路径心肌梗死诊断率为9%(95%CI 8%至11%),常规路径为8%(95%CI 6%至10%)。
- hs-cTnI路径住院率为42%(95%CI 39%至45%),常规路径为43%(95%CI 40%至47%)。
- hs-cTnI结果对治疗医生设盲,路径评估为回顾性判定,作者结论认为该路径30天MACE率可接受。
适用人群与场景
- 2019年6月至9月在急诊就诊的疑似心肌梗死患者,共935例。
诊断标准与关键阈值
- 常规cTnI(AccuTnI+3):检测限10 ng/L,第99百分位参考上限40 ng/L,异常升高切点80 ng/L。
- Access hsTnI:检测限2 ng/L,第99百分位参考上限女性10 ng/L、男性20 ng/L,异常升高定义为超过参考上限且变化值>30%。
- 低危与非低危患者分别依据ED Assessment of Chest pain score判定,常规cTnI采样时间为到达时及90分钟(低危)或360分钟(非低危),hs-cTnI采样时间为到达时及90分钟或180分钟。
处置流程与药物剂量
- 常规路径:依据常规cTnI结果和ED Assessment of Chest pain score指导诊断与处置,处置由治疗医生决定。
- hs-cTnI路径(回顾性判定):hs-cTnI显著升高者建议住院。
- 治疗医生对hs-cTnI结果设盲,不据此改变临床决策。
研究设计与关键结果
- 回顾性分析,935例疑似心肌梗死急诊患者,常规cTnI路径与Access hsTnI路径的出院后30天非预期MACE率均为0/935(0%,95%CI 0%至0.4%)。
- hs-cTnI与常规cTnI相比:异常升高率29%(95%CI 26%至32%)vs 19%(95%CI 17%至22%);心肌梗死诊断率9%(95%CI 8%至11%)vs 8%(95%CI 6%至10%);住院率42%(95%CI 39%至45%)vs 43%(95%CI 40%至47%)。
证据类型、等级与局限
- 证据类型:回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,采用Access hsTnI检测的新型路径具有可接受的低30天MACE率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: High-sensitivity cardiac troponin I (hs-cTnI) assays promise high diagnostic accuracy for myocardial infarction (MI). In an ED where conventional cTnI was in use, we evaluated an assessment pathway using the new Access hsTnI assay.
METHODS: This retrospective analysis recruited ED patients with suspected MI between June and September 2019. All patients received routine care with a conventional cTnI assay (AccuTnI +3: limit of detection (LoD) 10 ng/L, 99th centile upper reference limit (URL) 40 ng/L, abnormal elevation cut-point 80 ng/L). Arrival, then 90-minute or 360-minute cTnI levels for low and non-low risk patients, respectively (ED Assessment of Chest pain score) guided diagnosis and disposition which was at treating physician discretion. The same patients had arrival and 90-minute or 180-minute samples drawn for hs-cTnI levels (Access hsTnI: LoD 2 ng/L, 99th centile URL 10 ng/L (females) and 20 ng/L (males); abnormal elevation above the URL and delta >30%). Treating physicians were blinded to the hs-cTnI results. Using the hs-cTnI values, investigators retrospectively assigned likely diagnosis, disposition and likelihood of a 30-day major adverse cardiac event (MACE). Admission was recommended for significantly rising hs-cTnI elevations. The primary objective was to demonstrate an acceptable unexpected 30-day post-discharge MACE rate of <1%. cTnI elevation rates, diagnostic outcomes and ED disposition were also compared between pathways.
RESULTS: For the 935 patients, unexpected 30-day post-discharge MACE rates were 0/935 (0%, 95% CI 0% to 0.4%) with the conventional or novel pathway. For the high-sensitivity and conventional assays, respectively, abnormal elevation rates were 29% (95% CI 26% to 32%) and 19% (95% CI 17% to 22%), for MI were 9% (95% CI 8% to 11%) and 8% (95% CI 6% to 10%), and for hospital admission were 42% (95% CI 39% to 45%) and 43% (95% CI 40% to 47%).
CONCLUSION: The novel pathway using the Access hsTnI assay has an acceptably low 30-day MACE rate.
参考来源
- Meek R, Cullen L, Lu ZX, et al. Potential impact of a novel pathway for suspected myocardial infarction utilising a new high-sensitivity cardiac troponin I assay. Emerg Med J. 2021. PMID: 34759013. doi:10.1136/emermed-2020-210812
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。